Coagulation factor XI (FXI) plays an important part in both venous and arterial thrombosis, rendering FXIa a potential target for the development of antithrombotic therapy. The kunitz protease inhibitor (KPI) domain of protease nexin-2 (PN2) is a potent, highly specific inhibitor of FXIa, suggesting its possible role in the inhibition of FXI-dependent thrombosis in vivo. Therefore, we examined the effect of PN2KPI on thrombosis in the murine carotid artery and the middle cerebral artery. Intravenous administration of PN2KPI prolonged the clotting time of both human and murine plasma, and PN2KPI inhibited FXIa activity in both human and murine plasma in vitro. The intravenous administration of PN2KPI into WT mice dramatically decreased the progress of FeCl 3 -induced thrombus formation in the carotid artery. Following a similar initial rate of thrombus formation with and without PN2KPI treatment, the propagation of thrombus formation after 10 minutes and the amount of thrombus formed were significantly decreased in mice treated with PN2KPI injection compared with untreated mice. In the middle cerebral artery occlusion model, the volume and fraction of ischemic brain tissue was significantly decreased in PN2KPI-treated compared with untreated mice. Thus, inhibition of FXIa by PN2KPI is a promising approach to antithrombotic therapy.
Introduction
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Coagulation factor XI (FXI) has an essential role both in maintaining normal hemostasis and in the pathogenesis of thrombosis (1) . Since deficiencies of factor XII (FXII), prekallikrein (PK), and and high M r kininogen (HK) are not associated with hemostatic abnormalities but FXI deficiency produces relatively mild, post-traumatic bleeding complications in ~50% of affected individuals (2-4), the more relevant pathway for activation of plasma FXI might be via feedback activation by thrombin or possibly autoactivation by FXIa (5, 6) . High levels of FXI constitute a risk factor for deep venous thrombosis (DVT) (7) and cardiovascular disease in women (8) . Although inherited FXI deficiency confers no protection against acute myocardial infarction (AMI) (9) , a large clinical study showed that the risk of DVT in the 10% of individuals in a population with the highest levels of FXI was >2-fold greater than that for the remaining 90% of the population, supporting the conclusion that elevated FXI levels constitute an important risk factor for venous thrombosis (7, 8, 10) . There is also a reduced incidence of ischemic stroke in patients with severe FXI deficiency (11) . One study followed 600 patients with a first episode of venous thromboembolism and found an increased risk of recurrence, especially among those with increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) and FXI (12) , whereas another study showed that increased levels of TAFI, but not FXI, increased the risk of venous thromboembolism in patients with FV Leiden carrier status (10) . These studies are consistent with the results of studies demonstrating increased rabbit jugular vein thrombolysis by FXI antibody neutralization because of diminished indirect activation of TAFI (13) . Two studies in mice with targeted FXI gene For personal use only. on October 28, 2017. by guest www.bloodjournal.org From deletion, either alone (14) or in combination with targeted deficiency of protein C (15) , showed protection from FeCl 3 -induced carotid thrombosis (14) or from early lethality caused by thrombosis in protein-C-deficient animals (15) . Another study reported the important role of FXI in the growth of arterial thrombi using a rabbit model of arterial thrombosis (16) , whereas another demonstrated the dependence of surface-and tissue-factor-initiated thrombus propagation on FXI in primates (17) . Finally, the majority of patients with the acute coronary syndrome and coronary artery disease with a history of AMI have increased levels of circulating FXIa that correlate with markers of coagulation and inflammation (18) and patients with severe FXI deficiency have a reduced incidence of DVT (19) . Thus FXI/XIa levels in plasma constitute an important thrombogenic factor, and either FXI or FXIa provide a potential target for antithrombotic therapy (20) .
Important control mechanisms exist for the regulation of coagulation protease activities, including FXIa. Serine protease inhibitors (referred to as SERPINs) have been shown to be physiological regulators of FXIa function in plasma, including protease nexin 1, antithrombin III, C1 inhibitor, α-1-protease inhibitor, and α-2-antiplasmin (reviewed in Ref 1) . Another class of inhibitors, referred to as kunins, have also been identified as important regulators of protease function in plasma. Thus, following platelet activation by physiological stimulators, protease nexin 2 (PN2) is secreted from α-granules into plasma and inhibits FXIa (21) (22) (23) . PN2, a kunitz-type inhibitor, is a ~120 kDa isoform of the Alzheimer's β-amyloid protein precursor (AβPP) that has been shown to be a For personal use only. on October 28, 2017. by guest www.bloodjournal.org From highly potent and physiologically relevant inhibitor of FXIa (21, 22, (24) (25) (26) (27) (29, 30) . Since BPTI has in the past been commonly utilized clinically to control plasma proteolysis during and after cardiopulmonary bypass surgery, it seems feasible to examine the in vivo inhibitory activity of the KPI domain of PN2 as an antithrombotic agent. Therefore, in the present study, we examined the effect of PN2KPI on thrombus formation in a murine model of FeCl 3 -induced carotid artery thrombosis and stroke in the mouse middle cerebral artery occlusion (MCAO) model.
Materials and Methods

Expression and purification of recombinant KPI (PN2KPI) domain of PN2.
The PN2KPI was expressed in Pichia pastoris and purified as reported (31) .
Briefly, the sequence of the PN2 gene which encodes the KPI domain was inserted into the expression vector PICα, and Pichia pastoris transfected with this expression vector was expanded in BMGY medium before transfer to BMMY and photographed using a Nikon DP70 camera (Nikon, Tokyo, Japan).
Middle cerebral artery occlusion (MCAO) model: The mice were anesthetized as described above. The body temperature was maintained at 37±0.5°C using a heating lamp and pad. The intraluminal filament method (32) was utilized to promote middle cerebral artery occlusion (MCAO). The ECA groups. Differences between the PN2KPI group and the control group were evaluated using a paired two-tailed t-test with statistical significance determined as p<0.05.
Results
The expression and purification of PN2KPI. The PN2KPI expressed in Pichia pastoris was highly purified (>98% pure) after passing through ion exchange and gel filtration columns, as previously reported (28, 31). The inhibitory effect against purified FXIa (K i 0.5-1.4 nM) was consistent with that previously reported (31).
The inhibition of blood plasma FXIa activity by recombinant KPI. The PN2KPI added to mouse plasma inhibited the APTT assay as shown in Figure   1A . The inhibitory effect of PN2KPI on the APTT was also observed in human plasma, as previously reported (31) . The coagulation times in the APTT assay were prolonged when different concentrations (0-50 μM) of PN2KPI were added to either human ( Figure 1B) or mouse ( Figure 1C ) plasma. However, the PN2KPI was a more potent and complete inhibitor of coagulation in human than in murine plasma. The IC 50 of the PN2KPI inhibitory effect in human plasma ( Figure 1B) was ~125 nM whereas in mouse plasma the IC 50 was ~2 μM ( Figure 1C ). Plasma samples withdrawn from PN2KPI-treated animals also demonstrated prolonged clotting times in the APTT assay (47.8±0.8 sec, mean of 5 determinations) and in the FXI activity assay (72.2±1.1 sec, mean of 5 determinations). When the clotting times obtained in the APTT assay and the FXI activity assay were plotted against their respective standard curves, the estimated plasma concentration of PN2KPI in mouse plasma after PN2KPI treatment was ~1-2μM, and the FXIa activity remaining in the murine plasma at concentrations of PN2KPI >2μM was ~25-50% of the activity in untreated murine plasma (see Figure 1C ).
Thrombus formation in the mouse model of FeCl 3 -induced carotid artery
thrombosis. Thrombus formation was initially observed ~3 minutes after FeCl 3 -induced carotid injury in both PN2KPI-treated and control animals, followed by a rapid growth phase of the thrombus until 10 minutes, during which no significant difference in thrombus size was recorded between the two groups of the mice (Figure 2a and 2b) . However, thrombus accumulation continued rapidly in control animals achieving a maximum plateau at 30-40 minutes after injury. In contrast, thrombus accumulation was curtailed after ~5 minutes post-injury in mice treated with PN2KPI, and in some PN2KPI-treated animals, small portions of formed thrombi were flushed away by the high rate of blood flow. When the growth of thrombus size was plotted against time in the two groups of animals (Figure 2c) , it was apparent that the initial rate of thrombus growth was similar during the initial 3-minute period after injury in the PN2KPI-treated and control animals, whereas after 5-7 minutes the PN2KPI-treated mice demonstrated a low-level plateau of thrombus accumulation, whereas the control group continued 
The murine middle cerebral artery occlusion (MCAO) model:
The introduction of a thread into the middle cerebral artery resulted intravascular thrombosis leading to ischemia of the mouse brain. Thus inhibition of thrombus formation alleviates the extent of the stroke (37) . As shown in Figure 4 , the inhibition of FXIa by PN2KPI (Fig. 4B ), compared with a vehicle-treated mouse (Fig. 4A ), as shown with TTC staining, reduced the ischemic volume and the fraction of ischemic brain post MCAO. When the volume of ischemic brain in a group (n=6) of PN2KPI-treated animals was compared with a control group (n=6) of vehicle-treated animals, a significant reduction in stroke volume and fraction was observed in the mice treated with PN2KPI as compared with those from control group (p<0.05, Figure 4C and Figure 4D ).
The tail bleeding time:
To determine the effect of PN2KPI-treatment on hemostasis, the tail bleeding time was measured in a group of six mice treated with PN2KPI, compared with six animals treated with vehicle. The bleeding time was similar (P>0.05) in PN2KPI-treated mice (2.02±0.73 min) compared with those in the control group (2.11±0. 49 
min). Thus the administration of PN2KPI to
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From mice, sufficient to inhibit both carotid artery thrombosis and ischemic stroke due to MCAO, had no effect on hemostasis.
Discussion
The initiation of blood coagulation in vivo follows the formation of the enzyme complex that occurs when FVII or FVIIa is assembled on the transmembrane protein tissue factor (TF) present in many cell types (38) . The complex of TF and FVIIa is almost immediately inhibited when a complex is formed between FXa and the tissue factor pathway inhibitor (TFPI) (39) . The loss of the TF effect, i.e., the shut-down of the extrinsic pathway, could also be a consequence of thrombus accumulating over the top of the source of TF. Thus, FXa generation results in the immediate inactivation of the enzyme complex that initially forms it (i.e., TF-FVIIa). Therefore, the formation of thrombin through the extrinsic pathway is transient and the continuous generation of thrombin by the intrinsic pathway is required to assure normal hemostasis (40) . FXI is required for normal functioning of the intrinsic pathway, and an alternative mechanism for the activation of FXI exists that is independent of the contact proteins. Recent studies in FXII knockout mice showed that FXII-deficiency protects mice from experimentally induced thrombosis without producing bleeding complications (42) . The FXI-deficient mouse model was similarly employed to demonstrate in various thrombosis models that FXI-deficiency also protects against thrombosis without a bleeding phenotype (43) . Therefore FXI/XIa is an ideal target for the development of inhibitors to prevent thrombotic events without an increased risk of bleeding complications (44) . Our present studies confirm this hypothesis, and demonstrate that PN2KPI, administered to WT mice to achieve a plasma concentration of ~1-2 μM inhibits the propagation of carotid thrombi in a murine FeCl 3 carotid injury model. Interestingly, the initial rate of thrombus formation (i.e., during the initial 3-7 minutes after injury) was not significantly affected in PN2KPI-treated mice compared with untreated animals. However, the subsequent propagation of thrombi was prevented in PN2KPI-treated
animals. This suggests that the initial formation of thrombi occurs in response to the formation of the FVIIa/TF complex after release of TF from injured tissue, and that the FXa generated by FVIIa activation is limited because it is immediately inhibited by TFPI (38) . Thus, the extrinsic pathway alone fails to sustain the stability and expansion of thrombosis. The present studies suggest that the intrinsic or consolidation pathway of coagulation, triggered by the generation of FXIa catalyzed by the initial thrombin burst via the FVIIa/TF pathway, is critical to the process of thrombus propagation observed in WT control mice but not in PN2KPI-treated mice.
The MCAO model of ischemic stroke is mediated by both thrombotic and inflammatory mechanisms (37) and deficiency of components of the intrinsic pathway are critically involved in infarct development (45) . Both FXII-deficient and FXI-deficient mice are protected from cerebral ischemia: the infarct volumes were 50% less in FXII-deficient compared with wild-type mice at 24 hours after MCAO and the brain infarct volumes were also markedly diminished in FXI knockout mice (46) . By suppression of FXIa activity, recombinant PN2KPI prevents stroke in the MCAO model and significantly reduces the infarct volumes.
Considering its presence in neuronal cells and platelets, it has been suggested that PN2 and other KPI-containing proteins (e.g., amyloid precursorlike protein-2 or APLP2) might function as potential cerebral anticoagulants (47, 48) . Consistent with the results of our present studies, it was found that overexpression of PN2/AβPP in the circulating platelets of transgenic mice For personal use only. on October 28, 2017. by guest www.bloodjournal.org From resulted in marked inhibition of cerebral thrombosis and larger intracerebral hematomas (47, 48) , whereas PN2/AβPP deletion in AβPP gene knockout mice resulted in increased cerebral thrombosis and reduced intracerebral hematomas (47) . The question raised by these elegant studies relates to the mechanism by which over-expression of PN2/AβPP can inhibit thrombosis and enhance hemorrhage and deletion of this kunitz inhibitor can promote thrombosis and inhibit hemorrhage. Our previous studies (28, 31) strongly suggest that the only plasma coagulation enzyme inhibited by physiological concentrations of PN2KPI achievable in normal human plasma is FXIa. Thus, FXIa is inhibited by PN2KPI with a K i~0 .5-1.0 nM, a concentration considerably higher than the virtually undetectable level of PN2/AβPP in plasma (22) , but well below the concentrations (3-5 nM) that can be achieved at physiologic concentrations of platelets after secretion from α-granules (22, 26) . Thus, in the vicinity of a platelet thrombus, the concentration of PN2/AβPP is likely to be sufficient to regulate FXIa activity, but insufficient to have any significant effect on other plasma serine proteases, K i values (183-5500 nM) for which are 36-fold to 1,100-fold higher than the inhibitor concentration (3-5 nM) achieved after platelet secretion (28).
There are a number of important issues to be addressed in considering PN2KPI as a candidate for antithrombotic therapy in humans. Firstly, as shown in Figure 1 , PN2KPI is a more potent and complete inhibitor of FXIa in human plasma than in murine plasma. This could prove to be either a benefit or a liabilty for human therapy. The fact that the mice retain ~25-50% FXI levels after For personal use only. on October 28, 2017. by guest www.bloodjournal.org From PN2KPI administration which protects them from MCAO strongly suggests that partial inhibition of FXIa suffices to protect the animals from cerebrovascular stroke. Secondly, since PN2KPI is a small protein with (presumeably) a short half-life, it would have to be injected at regular intervals, which however might be prolonged by the construction of fusion proteins (49) . Thirdly, the administration of PN2KPI prior to the induction of thrombosis, e.g., in the MCAO model, while it provides proof of principle on the mechanism and effectiveness of the inhibitor, does not represent a real-life situation for human use, in which the PN2KPI would be administered after the appearance of symptoms due to cerebral artery thrombosis. Future studies are planned to examine the effectiveness of PN2KPI administered during middle cerebral artery occlusion and also immediately after restoration of the circulation when reperfusion injury begins. Moreover, studies are planned to investigate the effectiveness of long-term expression of the PN2KPI gene in mice, a strategy that might be employed in the prevention of cerebrovascular stroke in patients at high risk for thromboembolism.
The rationale for utilizing PN2KPI as an antithrombotic agent is based in part on the striking structural homology between the human FXIa/KPI complex (31) and the bovine trypsin/BPTI complex (50) , in addition to the fact that BPTI (as Trasylol ® ) has in the past been frequently utilized therapeutically in human subjects in the treatment and prevention of hemorrhage, e.g. in patients undergoing cardiopulmonary bypass surgery . However, it is no longer employed clinically because of numerous adverse reactions, including anaphylaxis. Since PN2KPI is a human protein, it is likely to be well tolerated when administered to FXI activity in human plasma (B) is inhibited by externally added PN2KPI and inhibitory activity is saturated at PN2KPI concentrations >10μM. Mouse FXI activity is ~75% inhibited by human KPI (C) and inhibitory activity is saturated at PN2KPI concentrations >10μM. 
